CA2830519A1 - Myelin regeneration with androgens - Google Patents

Myelin regeneration with androgens Download PDF

Info

Publication number
CA2830519A1
CA2830519A1 CA2830519A CA2830519A CA2830519A1 CA 2830519 A1 CA2830519 A1 CA 2830519A1 CA 2830519 A CA2830519 A CA 2830519A CA 2830519 A CA2830519 A CA 2830519A CA 2830519 A1 CA2830519 A1 CA 2830519A1
Authority
CA
Canada
Prior art keywords
receptor ligand
androgen
androgen receptor
testosterone
ment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2830519A
Other languages
English (en)
French (fr)
Inventor
Regine Sitruk-Ware
Michael Maria Helmut Schumacher
Abdelmouman Ghoumari
Said GHANDOUR
Rashad HUSSAIN
Bartosz BIELECKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Population Council
Original Assignee
Population Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council filed Critical Population Council
Publication of CA2830519A1 publication Critical patent/CA2830519A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
CA2830519A 2011-03-22 2012-03-22 Myelin regeneration with androgens Abandoned CA2830519A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161466252P 2011-03-22 2011-03-22
US61/466,252 2011-03-22
PCT/US2012/030041 WO2012129365A1 (en) 2011-03-22 2012-03-22 Myelin regeneration with androgens

Publications (1)

Publication Number Publication Date
CA2830519A1 true CA2830519A1 (en) 2012-09-27

Family

ID=45931036

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2830519A Abandoned CA2830519A1 (en) 2011-03-22 2012-03-22 Myelin regeneration with androgens

Country Status (7)

Country Link
US (1) US9364488B2 (enExample)
EP (1) EP2688571A1 (enExample)
JP (1) JP2014508809A (enExample)
BR (1) BR112013024084A2 (enExample)
CA (1) CA2830519A1 (enExample)
MX (1) MX2013010749A (enExample)
WO (1) WO2012129365A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6426783B2 (ja) * 2017-03-14 2018-11-21 ファナック株式会社 パワー素子の異常検知機能を備えたモータ駆動装置
KR102904262B1 (ko) 2018-01-11 2025-12-24 엠 이티 피 파마 아게 탈수초성 질환의 치료

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US6767902B2 (en) 1997-09-17 2004-07-27 The Population Council, Inc. Androgen as a male contraceptive and non-contraceptive androgen replacement
EP1358881A1 (en) 2002-04-30 2003-11-05 Schering Aktiengesellschaft Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
AUPS317302A0 (en) 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
EP2698167A3 (en) 2005-09-26 2014-03-05 The Regents of The University of California Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis
BR112012009306A2 (pt) 2009-10-19 2016-06-07 Population Coucil Inc método para regeneração de mielina em um paciente

Also Published As

Publication number Publication date
JP2014508809A (ja) 2014-04-10
US20140011791A1 (en) 2014-01-09
WO2012129365A4 (en) 2012-11-29
EP2688571A1 (en) 2014-01-29
WO2012129365A1 (en) 2012-09-27
BR112013024084A2 (pt) 2016-12-06
US9364488B2 (en) 2016-06-14
MX2013010749A (es) 2013-10-17

Similar Documents

Publication Publication Date Title
US10052335B2 (en) Neuroprotection and myelin repair using Nestorone®
Jung-Testas et al. Steroid hormone receptors and steroid action in rat glial cells of the central and peripheral nervous system
Bassani et al. Progestogen-mediated neuroprotection in central nervous system disorders
Baulieu et al. Progesterone as a neurosteroid: actions within the nervous system
Micevych et al. Neuroprogesterone: key to estrogen positive feedback?
Garcia-Segura et al. Aromatase: a neuroprotective enzyme
Pluchino et al. Progesterone and progestins: Effects on brain, allopregnanolone and β-endorphin
Brinton et al. Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease
ME01123B (me) Režim doziranja antiprogestina
Fanton et al. Activational action of testosterone on androgen receptors protects males preventing temporomandibular joint pain
Orozco et al. Dutasteride combined with androgen receptor antagonists inhibit glioblastoma U87 cell metabolism, proliferation, and invasion capacity: Androgen regulation
EP1929291A2 (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
US9364488B2 (en) Myelin regeneration with androgens
US9446051B2 (en) Neuroprotection and myelin repair using nestorone®
HRP20040370A2 (en) Use of (11 , 17 )-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
EP2745847A1 (en) Progestins for preventing or reducing neurodeneration or ischemic damage
Burton et al. Effectiveness of antiandrogens in the rat
Sitruk-Ware et al. Patent: Neuroprotection and myelin repair using Nestorone®
Paaske AVPV kisspeptin neurons mediate neuroprogesterone induction of the luteinizing hormone surge
Garay et al. Sex steroids, neurosteroidogenesis, and inflammation in multiple sclerosis and related animal models
WO1993007877A1 (en) Method for memory enhancement and quality of life improvement
Clemens The Aromatization Hypothesis
BR102013033185A2 (pt) método de tratamento de neurodegeneração e de dano isquêmico em um paciente
Schumacher et al. Aging Myelin and Cognitive Decline: a Role for Steroids
Cornia et al. Male hormonal contraception

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130917

FZDE Dead

Effective date: 20181003